Testicular cancer is staged from 0 through III, based on how far the tumor has grown, whether it has reached lymph nodes, whether it has spread to distant organs, and how high certain protein levels in the blood have risen. Unlike most other cancers, testicular cancer staging includes a fourth factor: blood markers. This unique addition makes the system more precise but also slightly more complex than what you may have seen for other cancers.
How Testicular Cancer Is Staged
The staging system used for testicular cancer is the AJCC TNM system, and it evaluates four things:
- T (tumor): How large the primary tumor is and whether it has grown beyond the testicle into surrounding tissue.
- N (nodes): Whether cancer has spread to nearby lymph nodes, particularly those in the back of the abdomen (retroperitoneal nodes), and how large those nodes have become.
- M (metastasis): Whether cancer has spread to distant parts of the body, such as the lungs, liver, or bones.
- S (serum markers): Blood levels of three proteins that testicular tumors often produce: LDH, hCG, and AFP. Higher levels indicate more cancer activity in the body.
To determine your stage, doctors combine findings from surgery (removing the affected testicle), imaging, and blood tests. Standard imaging includes a CT scan of the abdomen and pelvis with contrast, plus chest imaging. PET scans are not used for initial staging. Blood marker levels are checked both before and after surgery, since post-surgery levels help reveal whether cancer remains elsewhere in the body.
Stage 0: Abnormal Cells in Place
Stage 0, sometimes called germ cell neoplasia in situ, means abnormal cells are present inside the testicle but haven’t formed an invasive tumor yet. Think of it as a pre-cancer. The cells haven’t grown into surrounding tissue, spread to lymph nodes, or entered the bloodstream. Blood markers are normal. Stage 0 is uncommon to find on its own and is typically discovered incidentally during a biopsy or procedure for another reason.
Stage I: Cancer Confined to the Testicle
In Stage I, the cancer is limited to the testicle and has not spread to lymph nodes or distant sites. This is the most common stage at diagnosis and carries a five-year survival rate of about 99%.
Stage I is subdivided based on tumor characteristics and blood markers:
- Stage IA: The tumor is confined to the testicle without lymphovascular invasion (meaning cancer cells haven’t entered nearby blood vessels or lymph channels). Blood markers are normal after surgery.
- Stage IB: The tumor may have grown into surrounding structures like the spermatic cord or scrotum, or it shows lymphovascular invasion, but it still hasn’t reached lymph nodes. Blood markers are normal after surgery.
- Stage IS: After the testicle is removed, blood marker levels remain elevated or rise, suggesting cancer is present somewhere even though imaging doesn’t show it. This substage is particularly important because it can change the treatment approach significantly.
Stage II: Spread to Retroperitoneal Lymph Nodes
Stage II means cancer has spread to lymph nodes in the retroperitoneum, the area behind the abdominal organs near the spine. These are the first lymph nodes testicular cancer typically reaches. The cancer has not spread to distant organs. Five-year survival for regional-stage testicular cancer is roughly 96%.
The substages are defined by how large the affected lymph nodes are:
- Stage IIA: Lymph node involvement where no mass is larger than 2 cm. Blood markers are normal or only mildly elevated (S0 or S1).
- Stage IIB: At least one lymph node mass is between 2 cm and 5 cm, or more than five nodes are positive. Blood markers are no higher than S1.
- Stage IIC: At least one lymph node mass is larger than 5 cm. Blood markers are no higher than S1.
The jump from IIA to IIC reflects a meaningful difference in tumor burden. A 2 cm lymph node is roughly the size of a peanut, while a 5 cm node is closer to a lime. Larger nodes generally mean more aggressive treatment is needed.
Stage III: Distant Spread
Stage III means cancer has spread beyond the retroperitoneal lymph nodes to distant sites, or blood markers are significantly elevated regardless of where visible disease appears. The five-year survival rate for distant-stage testicular cancer is about 72%, which is still considerably higher than most other cancers at this stage.
Stage III is broken into three substages that reflect escalating severity:
- Stage IIIA: Cancer has spread to distant lymph nodes outside the retroperitoneum or to the lungs, but blood markers are only mildly elevated (S1).
- Stage IIIB: Cancer may be in distant lymph nodes or lungs, with moderately elevated blood markers (S2). In the S2 range, at least one marker is notably high: LDH between 1.5 and 10 times normal, hCG between 5,000 and 50,000, or AFP between 1,000 and 10,000.
- Stage IIIC: Cancer has spread to organs other than the lungs (such as the liver, brain, or bones), or blood markers are very high (S3), or both. S3 means LDH is more than 10 times normal, hCG exceeds 50,000, or AFP exceeds 10,000.
The distinction between lung-only spread and spread to other organs matters. Lung metastases respond well to chemotherapy and carry a better prognosis than liver or brain involvement, which is why the staging system treats them differently.
Why Blood Markers Matter So Much
Testicular cancer is one of the few cancers where blood tests directly affect the stage. Three markers are measured: AFP (alpha-fetoprotein), hCG (human chorionic gonadotropin), and LDH (lactate dehydrogenase). Each reflects different aspects of tumor activity.
The markers are grouped into four levels:
- S0: All markers normal.
- S1: At least one marker elevated, but all remain relatively low (LDH under 1.5 times normal, hCG under 5,000, AFP under 1,000).
- S2: Moderate elevation in at least one marker.
- S3: Very high elevation in at least one marker.
A patient with no visible spread on imaging but persistently rising markers after surgery is classified as Stage IS rather than Stage IA, which typically leads to chemotherapy rather than surveillance alone. Conversely, someone with distant spread but low markers has a better outlook than someone with equally widespread disease and sky-high markers.
Seminoma vs. Non-Seminoma
Testicular cancer comes in two broad types: seminomas and non-seminomas. Both use the same staging system, but the tumor type influences treatment and prognosis at every stage.
Seminomas tend to grow more slowly and are extremely sensitive to radiation and chemotherapy. They rarely produce AFP, so an elevated AFP level almost always points to a non-seminoma component even if the pathology looks like pure seminoma. Non-seminomas are more likely to spread early and can produce all three markers. They also tend to require more aggressive treatment at equivalent stages.
At the advanced-disease level, seminomas are never classified in the poorest prognostic group. Even with distant spread, seminomas fall into either the good or intermediate prognosis category. Non-seminomas, on the other hand, can land in the poor prognosis group when markers are very high (S3) or when cancer has spread to organs beyond the lungs.
What Each Stage Means in Practice
Stage I is often managed with active surveillance after surgery, meaning regular imaging and blood work to catch any recurrence early. Some patients with higher-risk Stage I disease receive a short course of chemotherapy or radiation to reduce recurrence risk, but many are simply monitored.
Stage II treatment depends on the substage and tumor type. Stage IIA seminoma may be treated with radiation or chemotherapy. Larger-volume Stage II disease and non-seminomas generally require chemotherapy, sometimes followed by surgery to remove residual lymph node masses.
Stage III is treated with chemotherapy, and the number of cycles depends on the prognostic group. Good-prognosis patients typically receive three cycles, while intermediate or poor-prognosis patients receive four. After chemotherapy, if masses remain on imaging, surgery may be performed to remove them. Even at Stage IIIC, testicular cancer responds to treatment more successfully than most advanced cancers, though the road is longer and more intensive.